Patient baseline
ONCOLOGY, LIVER METASTASIS, BRAIN METASTASIS
From March 2020 to December 2021, 19 ES-SCLC patients were enrolled in this study and received study medications. Of them, the median age was 63 (range 51-70) years old, and 17 (89.5%) patients were male. Most patients (89.5%) were stage IV. Two patients had liver metastasis and one patient experienced brain metastasis (Baseline characteristics of patients.EP/EC, (etoposide plus cisplatin, or etoposide plus carboplatin); IP/IC, (irinotecan plus cisplatin, or irinotecan plus carboplatin); ECOG PS, Eastern Cooperative Oncology Group performance status; dNLR, modified neutrophil to lymphocyte ratio; LDH, lactate dehydrogenase; ProGRP, pro-gastrin releasing peptide; NSE, neuron-specific enolase; ULN, upper limit of normal; ICI, immune checkpoint inhibitor.*The smoking index was calculated as cigarettes per day x duration of smoking (years).In addition, a total of 54 ES-SCLC patients received ICIs combined with chemotherapy as the first-line treatment were retrospective reviewed form January 2013 to December 2021, of which 34 patients treated with EP/EC combined with a PD-L1 inhibitor (atezolizumab or durvalumab) were selected as the historical control group. The median age of these patients was 64 (range 42-77) years old and 27 (79.4%) patients were male. Two patients had an ECOG PS score of 2 or above. The majority (97.1%) were stage IV. Six (17.6%) and three (8.8%) patients had liver metastasis and brain metastasis, respectively. There were no significant differences in the baseline characteristics of patients between two groups (